NCT06896188 - 9-ING-41 Combined With Retifanlimab, Plus Modified FOLFIRINOX for Patients With Advanced Pancreatic Adenocarcinoma (RiLEY) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 22, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2028

Conditions

Pancreatic Adenocarcinoma

Interventions

DRUG

Retifanlimab

(PD-1)-blocking monoclonal antibody

DRUG

Chemotherapy

oxaliplatin - Antineoplastic - Platinum Complexes Chemotherapy agent; leucovorin - a form of Folic acid helps the body produce and maintain new cells, and also helps prevent changes to DNA that may lead to cancer; irinotecan - anti-cancer medication used to treat colon cancer in combination with other chemotherapeutic agents; 5-FU - 5-fluorouracil is used to treat cancer in combination with other chemotherapeutic agents

DRUG

9-ING-41

a maleimide-based ATP-competitive and selective glycogen synthase kinase-3β (GSK-3β) inhibitor with an IC50 of 0.71 μM. 9-ING-41 significantly leads to cell cycle arrest, autophagy and apoptosis in cancer cells

Trial Locations (1)

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh